Key clinical point: Ixekizumab as monotherapy or in combination with methotrexate or conventional synthetic disease-modifying antirheumatic drugs (csDMARD) demonstrated sustained efficacy through 3 years in patients with psoriatic arthritis (PsA). Ixekizumab had a similar and consistent safety profile.
Major finding: At week 156, similar proportions of patients receiving ixekizumab, ixekizumab+methotrexate, and ixekizumab+any csDMARD achieved ≥ 20% improvement in American College of Rheumatology score (59.1%, 67.0%, and 66.1%, respectively) and reported ≥1 treatment-emergent adverse events (91.0%, 84.1%, and 83.2%, respectively) of mostly mild or moderate severity.
Study details: Findings are from a post hoc analysis of 2 phase 3 trials, SPIRIT-P1 and SPIRIT-P2, including 202 patients with active PsA who were biologic-naive or had prior inadequate response to tumor necrosis factor inhibitors and were randomly assigned to receive ixekizumab, ixekizumab+methotrexate, or ixekizumab+any csDMARD.
Disclosures: This study was funded by Eli Lilly and Company. Five authors reported employment or stock ownership with Eli Lilly, and other authors reported ties with several sources, including Eli Lilly.
Source: Coates LC et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results. Clin Rheumatol. 2022 (Jun 8). Doi: 10.1007/s10067-022-06218-8